HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)

Grants

Funding Acknowledgements

We would like to express our gratitude to the many families who participated in the studies involved in the International Consortium for Prostate Cancer Genetics (ICPCG). The ICPCG is funded by a grant from the National Institutes of Health U01 CA89600 (to W. B. I.). Additional support to members within the ICPCG is as follows: University of Michigan Group acknowledges NIH grants R01 CA79596, R01 CA079596-10-S1 (ARRA), R01 CA136621, and P50 CA69568. University of Utah Group: The authors thank the support from the University of Utah Huntsman Cancer Institute (to Lisa A. Cannon-Albright). FHCRC/NHGRI Group: Partial support was provided by the Fred Hutchinson Cancer Research Center (to Janet L. Stanford) and National Human Genome Research Institute (to Elaine A. Ostrander). ACTANE Group: We acknowledge support from CR-UK grant C5047/A7357 and the NIHR to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust and Prostate Action (to Ros Eeles), and Cancer Research UK (to Doug Easton). This work was also supported by the European Commission's Seventh Framework Programme grant agreement no 223175 (HEALTH-F2-2009-223175), University of Umea Group: Partial support was provided by Swedish Cancer Society and a Spear grant from the Umea University Hospital, Umea, Sweden (to Henrik Gronberg). University of Tampere Group: Partial support was provided from The Competitive Research Funding of the Pirkanmaa Hospital District (9M094), Finnish Cancer Organisations, Sigrid Juselius Foundation and Academy of Finland (116437 and 251074) (to Johanna Schleutker). Australian Group: Recruitment was funded by Cancer Council Victoria, Tattersalls and The Whitten Foundation; JLH is an Australia Fellow of the National Health and Medical Research Council. Northwestern University Group: Partial support was provided from Robert H Lurie Comprehensive Cancer Center and the Urological Research Foundation (to William J. Catalona). LSUHSC-NO Group: Louisiana Board of Regents, Centers for Disease Control and Prevention. Data Coordinating Center: Partial support was provided by NCI CA119069 and CA129684 (to Jianfeng Xu). We also thank other investigators who contributed to this work: ACTANE Group: Daniel Leongamornlert, Ed Saunders, Malgorzata Tymrakiewicz, Lynne O'Brien, Emma Sawyer, Rosemary Wilkinson, and Stephen Edwards from The Institute of Cancer Research, Sutton, Surrey; Jacques Simard, from the Human Molecular Endocrinology Research Center, CHUL Research Center, Laval University, Quebec City, Canada; Timothy Bishop from Cancer Research UK, Genetic Epidemiology Laboratory, St James' University Hospital, Leeds, UK; Michael Badzioch; Tokhir Dadaev, Lesley McGuffog, Koveela Govindasami, and Michelle Guy from the UKGPCS Team. University of Ulm Group: Antje Rinckleb and Mark Schrader from Department of Urology, University of Ulm, Germany; Josef Hoegel and Christian Kubisch from Institute of Human Genetics, University of Ulm, Germany; and Kathleen Herkommer from Department of Urology, Technical University of Munich, Germany. Fred Hutchinson Cancer Research Center Group: Laura McIntosh. We thank Liesel FitzGerald for helpful comments and review. William Foulkes thanks Celia Greenwood for advice.